Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports from University of Sheffield, Medical Academy add new data to research in breast cancer
November 13th, 2008
"New efforts are being focused on signalling pathways as targets for cancer therapy. This particular study was designed to investigate whether blockade of the phosphatidylinositol 3OH-kinase (PI3K) pathway (a survival/anti-apoptosis pathway, overexpressed in various tumours) could sensitise human breast cancer cells to the effect of chemotherapeutics," scientists in Sheffield, the United Kingdom report. "Doxorubicin (Dox) and LY294002 (LY, a PI3K inhibitor) were used individually or in combination on MDA-MB-231 (p53 mutant, ER-), T47D p53 mutant, ER+), and MCF-7 (p5.3 wildlype, ER+) human breast cancer cell lines, and on 184A1, a nonmalignant human breast epithelia]...
Source: Women's Health Weekly (2008-11-13)
|
